NASDAQ:ANTX Anthem Q1 2026 Earnings Report $5.21 -0.40 (-7.06%) As of 12:12 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Anthem EPS ResultsActual EPS-$0.29Consensus EPS -$0.23Beat/MissMissed by -$0.06One Year Ago EPSN/AAnthem Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAnthem Announcement DetailsQuarterQ1 2026Date5/11/2026TimeAfter Market ClosesConference Call DateMonday, May 11, 2026Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Anthem Earnings HeadlinesAN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSKSeptember 28, 2026 | businesswire.comAN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)September 16, 2026 | businesswire.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 6 at 1:00 AM | Profits Run (Ad)AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual MeetingAugust 31, 2026 | businesswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)July 20, 2026 | prnewswire.comAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas DiseaseJune 4, 2026 | businesswire.comSee More Anthem Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Anthem? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anthem and other key companies, straight to your email. Email Address About AnthemAnthem (NASDAQ:ANTX) is not currently associated with the Nasdaq ticker ANTX. The former Anthem, Inc. changed its name to Elevance Health, Inc. in 2022 and trades under the ticker ELV. ANTX is the ticker for AN2 Therapeutics, Inc., a separate biotechnology company. AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly conditions for which existing therapies are limited. Its research has centered on novel anti-infective medicines and diseases affecting underserved patient populations. The company’s lead investigational product has been epetraborole, an oral therapy studied for pulmonary disease caused by Mycobacterium avium complex, a difficult-to-treat bacterial infection. AN2 Therapeutics is based in the United States and has conducted clinical development activities internationally. Information provided here describes AN2 Therapeutics rather than Anthem or Elevance Health because of the ticker discrepancy.View Anthem ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
